Boost for Exelixis as partner Daiichi Sankyo cues up hypertension drug filing
fiercebiotech | September 25, 2017
With a positive phase 3 trial in hand, Japan’s Daiichi Sankyo plans to file its essential hypertension therapy esaxerenone in its home market next year. It’s a big step forward for the company’s 11-year partnership with Exelixis on drugs that target the mineralocorticoid receptor (MR). It sets the U.S. biotech on course for a third product approval that it says could generate “substantial” milestones plus low-double-digit royalties on sales.